Abnormalities of cardiac rhythm are a major public health problem. Drugs suppress cardiac arrhythmias in some patients, yet exacerbate arrhythmias or even generate new ones - the phenomenon of proarrhythmia - in others. This variability is not confined to antiarrhythmic drugs alone: in fact, the risk of proarrhythmia related to excessive prolongation of the QT interval has been the single leading cause of drug withdrawal over the past decade. While rare monogenic arrhythmia syndromes have been recognized for decades, more recent work strongly supports the overall hypothesis tested here, that common DMA variants underlie not only variability in cardiac rhythm but also the response of normal and abnormal cardiac rhythms to drug exposure.
In Specific Aim 1, we will identify coding and non-coding variants and haplotypes in genes that are candidate modulators of cardiac rhythm, and functionally characterize these in vitro;these studies will inform the refinement of our current multiplexed arrhythmia genotyping platforms.
In Specific Aim 2, we propose a series of studies to define genomic contributors to variable QT responses to drug therapy.
In Specific Aim 3, variability in drug response in atrial fibrillation, the commonest arrhythmia for which drug therapy is currently prescribed, will be evaluated;here, we include a focus on """"""""non-traditional"""""""" signaling pathways, such as the renin-angiotensin system and inflammation, that contemporary electrophysiology increasingly implicates in this arrhythmia.
The Specific Aims will be supported by scientific Core resources devoted to ascertainment, DMA banking, database management, epidemiology and statistics, polymorphism discovery, genotyping, and functional studies. Participation in the Network will enable the long-term vision of exploiting human genomic information for more rationale drug development and
| Klein, Teri E; Ritchie, Marylyn D (2018) PharmCAT: A Pharmacogenomics Clinical Annotation Tool. Clin Pharmacol Ther 104:19-22 |
| Bergmeijer, Thomas O; Reny, Jean-Luc; Pakyz, Ruth E et al. (2018) Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). Am Heart J 198:152-159 |
| Hall, Molly A; Wallace, John; Lucas, Anastasia et al. (2017) PLATO software provides analytic framework for investigating complexity beyond genome-wide association studies. Nat Commun 8:1167 |
| Chhibber, A; French, C E; Yee, S W et al. (2017) Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell lines. Pharmacogenomics J 17:137-145 |
| Yang, Zhenjiang; Prinsen, Joseph K; Bersell, Kevin R et al. (2017) Azithromycin Causes a Novel Proarrhythmic Syndrome. Circ Arrhythm Electrophysiol 10: |
| Moore, Carrie Colleen Buchanan; Basile, Anna Okula; Wallace, John Robert et al. (2016) A biologically informed method for detecting rare variant associations. BioData Min 9:27 |
| Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68 |
| Roden, Dan M (2016) Pharmacogenetics of Potassium Channel Blockers. Card Electrophysiol Clin 8:385-93 |
| Lin, Honghuang; Mueller-Nurasyid, Martina; Smith, Albert V et al. (2016) Gene-gene Interaction Analyses for Atrial Fibrillation. Sci Rep 6:35371 |
| Kim, Dokyoon; Lucas, Anastasia; Glessner, Joseph et al. (2016) BIOFILTER AS A FUNCTIONAL ANNOTATION PIPELINE FOR COMMON AND RARE COPY NUMBER BURDEN. Pac Symp Biocomput 21:357-68 |
Showing the most recent 10 out of 258 publications
